TGF-β was shown to switch from tumor-suppressor to prometastatic factor with disease progression in both a HER2/Neu-driven genetically engineered mouse model and a Ras-driven human xenograft model of breast cancer [24,25]. Here, ERBB2 is linked to breast carcinoma.